Anti-PD-L1 (Atezolizumab), humanized Antibody

CATALOG NO: A1305-100

ALTERNATE NAMES: Tecentriq

AMOUNT: 100 µg

IMMUNOGEN: Human programmed cell death 1 ligand 1 (PD-L1)

HOST/ISOTYPE: Human IgG1

CLONALITY: Monoclonal

SOURCE: CHO cells

ENDOTOXIN LEVELS: < 0.05 EU/ml

PURIFICATION: IgG purified from CHO culture supernatant by protein A chromatography

SPECIES REACTIVITY: Human

FORM: Liquid

FORMULATION: Supplied in phosphate buffered saline, pH 7.4

STORAGE CONDITIONS: For long term storage store at -20°C. Once thawed, keep it at 4°C.

SPECIFICITY: Tecentriq (bio-similar) is an Fc engineered, humanized monoclonal antibody that binds to PD-L1 and blocks interaction with the PD-2 and B7.1 receptors. Tecentriq (bio-similar) is a non-glycosylated IgG1 Kappa immunoglobulin that has a calculated molecular mass of 145 kDa.

DESCRIPTION: Atezolizumab (trade name Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab blocks the interaction of PD-L1 with PD-1 and induces anti-tumor immune reactivation.

APPLICATION: Neutralization: 0.1-1 µg/ml, ELISA: 1 µg/ml

FOR RESEARCH USE ONLY! Not to be used on humans.

FOR RESEARCH USE ONLY! Not to be used on humans.